DURECT Corporation Invites You to Join its Fourth Quarter 2013 Earnings Conference Call and Upcoming Investor Conference

Download PDF:

CUPERTINO, Calif., Feb. 18, 2014 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, February 27, 2014 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

In addition, on Monday, March 3, 2014 at 8:10 a.m. Eastern time, James E. Brown, President and CEO, will present at the 24th Annual Investor Conference hosted by the Wall Street Analyst Forum.  The conference is being held at the University Club in New York City.  A live audio webcast of the presentation will be available by accessing www.visualwebcaster.com/event.asp?id=98054.

A live audio webcast of these presentations will be available by accessing DURECT’s homepage at http://www.www.durect.com and clicking “Investor Relations.”  If you are unable to participate during the live webcast, the call will be archived on DURECT’s website under Audio Archive in the “Investor Relations” section.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT’s proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.www.durect.com.

NOTE: POSIDUR, SABER®, ORADUR®, TRANSDUR®, and ELADUR® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.


Matthew J. Hogan, Chief Financial Officer, 408-777-4936

Scroll to Top